Amicus Therapeutics Strengthens Executive Leadership Team

CRANBURY, N.J., Feb. 09, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, has strengthened its executive leadership with the addition of two new members with significant experience in rare disease. Ellen S. Rosenberg, a biopharmaceutical legal executive with strong commercial experience, most recently as Shire Pharmaceuticals’ Head of U.S. Legal, has been appointed General Counsel and Corporate Secretary. Kurt J.W. Andrews, a Human Resources executive with more than 20 years of experience, most recently at Valeritas, Inc. and PTC Therapeutics, Inc., has been named Senior Vice President, Human Resources. Both Ms. Rosenberg and Mr. Andrews will report to John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc.

Ellen S. Rosenberg – General Counsel and Corporate Secretary

Ms. Rosenberg will have global responsibility for all legal issues, provide counsel and advice to the leadership team, and provide legal oversight for the commercial expansion at Amicus. She has more than 25 years of legal experience in the biopharmaceutical and medical device industry. Ms. Rosenberg joins Amicus from Shire Pharmaceuticals, LLC, where she most recently served as Senior Vice President, Associate General Counsel. In this role she functioned as the Head of Shire’s U.S. legal group with responsibility for all legal matters arising from Shire’s U.S. business, including mergers and acquisitions, product launches, risk management, and compliance matters. Prior to Shire, Ms. Rosenberg was Associate General Counsel for the Metabolic Endocrinology division at EMD Serono Inc., the U.S. affiliate of Merck KGaA. Ms. Rosenberg received a B.A. from the University of Connecticut and a J.D. from the University of Pennsylvania Law School.

Kurt J.W. Andrews - Senior Vice President, Human Resources

Mr. Andrews will be responsible for developing the human resources strategy and plans to support the Amicus vision, including organizational structure, talent development, compensation strategy, and efforts to recruit and retain top talent. He has more than 20 years of experience working in leadership roles at biotechnology and technology companies. He most recently served as Vice President, Human Resources at Valeritas, Inc., a commercial-stage medical technology company, where he helped lead the evolution of the organization’s business and commercial strategy, implementation of organization-wide goals and strategies, performance management, and compensation planning. Previously Mr. Andrews was Vice President, Human Resources and Administration at PTC Therapeutics, Inc. Mr. Andrews earned a B.A. and M.A. from The University of Illinois at Urbana-Champaign.

John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc., stated, “Ellen and Kurt are two very valuable additions to our executive leadership team, and I am pleased to welcome them to Amicus. Our legal and human resources functions will provide critical support as we continue to build Amicus into one of the most significant and lasting global biotechnology companies, focused on novel treatments for people living with devastating rare diseases. Both Ellen and Kurt have significant experience in rare diseases and a true passion for patients that make them a perfect fit with our culture. We believe that our Amicus team is stronger than ever as we prepare for commercialization and continue to advance our pipeline of novel therapies for patients living with rare diseases.”

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq:FOLD) is a biotechnology company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of advanced therapies for a broad range of human genetic diseases. Amicus’ lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as novel enzyme replacement therapy (ERT) products for Fabry disease, Pompe disease, and other Lysosomal Storage Disorders.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of Amicus' candidate drug products, the timing and reporting of results from preclinical studies and clinical trials evaluating Amicus' candidate drug products and the projected cash position for the Company. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "potential," "plan," "targets," "likely," "may," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing and outcomes of discussions with regulatory authorities and the potential goals, progress, timing and results of preclinical studies and clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the business of Amicus, including, without limitation: the potential that results of clinical or pre-clinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that regulatory authorities may not grant or may delay approval for our product candidates; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; the potential that we will need additional funding to complete all of our studies and, our dependence on third parties in the conduct of our clinical studies. Further, the results of earlier preclinical studies and/or clinical trials may not be predictive of future results. With respect to statements regarding projections of the Company's cash position, actual results may differ based on market factors and the Company's ability to execute its operational and budget plans. In addition, all forward looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2014 and Form 10-Q for the quarter ended June 30, 2015. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Amicus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.


CONTACTS: Investors/Media: Amicus Therapeutics Sara Pellegrino Senior Director, Investor Relations (609) 662-5044 Media: Pure Communications Dan Budwick (973) 271-6085

Source:Amicus Therapeutics, Inc